Search NASA⌕ Search

SEARCH · Search NASA

Results for “Boosting”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7

High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes

Purpose: This is a retrospective study comparing our experience with high-dose-rate (HDR) brachytherapy boost for prostate cancer, using two different fractionation schemes, 600 cGy Multiplication-Sign 3 fractions (patient group 1) and 950 cGy Multiplication-Sign 2 fractions (patient group 2). Methods and Materials: A total of 165 patients were treated for prostate cancer using external beam radiation therapy up to a dose of 45 Gy, followed by an HDR brachytherapy prostate radiation boost. Between July 1997 and Nov 1999, 64 patients were treated with an HDR boost of 600 cGy Multiplication-Sign 3 fractions; and between June 2000 and Nov 2005, 101 patients were treated with an HDR boost of 950 cGy Multiplication-Sign 2 fractions. All but 9 patients had at least one of the following risk features: pretreatment prostate-specific antigen (PSA) level >10, a Gleason score {>=}7, and/or clinical stage T3 disease. Results: Median follow-up was 105 months for group 1 and 43 months for group 2. Patients in group 2 had a greater number of high-risk features than group 1 (p = 0.02). Adjusted for comparable follow-up, there was no difference in biochemical no-evidence-of-disease (bNED) rate between the two fractionation scheme approaches, with 5-year Kaplan-Meier estimates of 93.5% in group 1 and 87.3% in group 2 (p = 0.19). The 5-year estimates of progression-free survival were 86% for group 1 and 83% for group 2 (p = 0.53). Among high-risk patients, there were no differences in bNED or PFS rate due to fractionation. Conclusions: Results were excellent for both groups. Adjusted for comparable follow-up, no differences were found between groups.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Subsets of Women With Close or Positive Margins After Breast-Conserving Surgery With High Local Recurrence Risk Despite Breast Plus Boost Radiotherapy

Purpose: (1) To examine the effect of surgical margin status on local recurrence (LR) and survival following breast-conserving therapy; (2) To identify subsets with close or positive margins with high LR risk despite whole breast radiotherapy (RT) plus boost. Methods and Materials: Subjects were 2,264 women with pT1-3, any N, M0 invasive breast cancer, treated with breast-conserving surgery and whole breast {+-} boost RT. Five-year Kaplan-Meier (KM) LR, breast cancer-specific and overall survival (BCSS and OS) were compared between cohorts with negative (n = 1,980), close (n = 222), and positive (n = 62) margins. LR rates were analyzed according to clinicopathologic characteristics. Multivariable Cox regression modeling and matched analysis of close/positive margin cases and negative margin controls were performed. Results: Median follow-up was 5.2 years. Boost RT was used in 92% of patients with close or positive margins. Five-year KM LR rates in the negative, close and positive margin cohorts were 1.3%, 4.0%, and 5.2%, respectively (p = 0.001). BCSS and OS were similar in the three margin subgroups. In the close/positive margin cohort, LR rates were 10.2% with age <45 years, 11.8% with Grade III, 11.3% with lymphovascular invasion (LVI), and 26.3% with {>=}4 positive nodes. Corresponding rates in the negative margin cohort were 2.3%, 2.4%, 1.0%, and 2.4%, respectively. On Cox regression analysis of the entire cohort, close or positive margin, Grade III histology, {>=}4 positive nodes, and lack of systemic therapy were significantly associated with higher LR risk. When close/positive margin cases were matched to negative margin controls, the difference in 5-year LR remained significant (4.25% vs. 0.7%, p < 0.001). Conclusions: On univariable analysis, subsets with close or positive margins, in combination with age <45 years, Grade III, LVI, and {>=}4 positive nodes, have 5-year LR >10% despite whole breast plus boost RT. These patients should be considered for more definitive surgery.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Phase II Study of Preoperative Helical Tomotherapy With a Simultaneous Integrated Boost for Rectal Cancer

Purpose: The addition of concomitant chemotherapy to preoperative radiotherapy is considered the standard of care for patients with cT3-4 rectal cancer. The combined treatment modality increases the complete response rate and local control (LC), but has no impact on survival or the incidence of distant metastases. In addition, it is associated with considerable toxicity. As an alternative strategy, we explored prospectively, preoperative helical tomotherapy with a simultaneous integrated boost (SIB). Methods and Materials: A total of 108 patients were treated with intensity-modulated and image-guided radiotherapy using the Tomotherapy Hi-Art II system. A dose of 46 Gy, in daily fractions of 2 Gy, was delivered to the mesorectum and draining lymph nodes, without concomitant chemotherapy. Patients with an anticipated circumferential resection margin (CRM) of less than 2 mm, based on magnetic resonance imaging, received a SIB to the tumor up to a total dose of 55.2 Gy. Acute and late side effects were scored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Results: A total of 102 patients presented with cT3-4 tumors; 57 patients entered the boost group and 51 the no-boost group. One patient in the no-boost group developed a radio-hypersensitivity reaction, resulting in a complete tumor remission, a Grade 3 acute and Grade 5 late enteritis. No other Grade {>=}3 acute toxicities occurred. With a median follow-up of 32 months, Grade {>=}3 late gastrointestinal and urinary toxicity were observed in 6% and 4% of the patients, respectively. The actuarial 2-year LC, progression-free survival and overall survival were 98%, 79%, and 93%. Conclusions: Preoperative helical tomotherapy displays a favorable acute toxicity profile in patients with cT3-4 rectal cancer. A SIB can be safely administered in patients with a narrow CRM and resulted in a promising LC.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Long-Term Follow-Up of Preoperative Pelvic Radiation Therapy and Concomitant Boost Irradiation in Locally Advanced Rectal Cancer Patients: A Multi-Institutional Phase II Study (KROG 04-01)

Purpose: To perform a prospective phase II study to investigate the efficacy and safety of preoperative pelvic radiation therapy and concomitant small-field boost irradiation with 5-fluorouracil and leucovorin for 5 weeks in locally advanced rectal cancer patients. Methods and Materials: Sixty-nine patients with locally advanced, nonmetastatic, mid-to-lower rectal cancer were prospectively enrolled. They had received preoperative chemoradiation therapy and total mesorectal excision. Pelvic radiation therapy of 43.2 Gy in 24 fractions plus concomitant boost radiation therapy of 7.2 Gy in 12 fractions was delivered to the pelvis and tumor bed for 5 weeks. Two cycles of 5-fluorouracil and leucovorin were administered for 3 days in the first and fifth week of radiation therapy. The pathologic response, survival outcome, and treatment toxicity were evaluated for the study endpoints. Results: Of 69 patients, 8 (11.6%) had a pathologically complete response. Downstaging rates were 40.5% for T classification and 68.1% for N classification. At the median follow-up of 69 months, 36 patients have been followed up for more than 5 years. The 5-year disease-free survival (DFS) and overall survival rates were 66.0% and 75.3%, respectively. Higher pathologic T (P = .045) and N (P = .032) classification were significant adverse prognostic factors for DFS, and high-grade histology was an adverse prognostic factor for both DFS (P = .025) and overall survival (P = .031) on the multivariate analysis. Fifteen patients (21.7%) experienced grade 3 or 4 acute toxicity, and 7 patients (10.1%) had long-term toxicity. Conclusion: Preoperative pelvic radiation therapy with concomitant boost irradiation with 5-fluorouracil and leucovorin for 5 weeks showed acceptable acute and long-term toxicities. However, the benefit of concomitant small-field boost irradiation for 5 weeks in rectal cancer patients was not demonstrated beyond conventional irradiation for 6 weeks in terms of tumor response and survival.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer

Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged {>=}18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Prospective Study of Local Control and Late Radiation Toxicity After Intraoperative Radiation Therapy Boost for Early Breast Cancer

Purpose: To report the local recurrence rate and late toxicity of intraoperative radiation therapy (IORT) boost to the tumor bed using the Intrabeam System followed by external-beam whole-breast irradiation (WBI) in women with early-stage breast cancer in a prospective single-institution study. Methods and Materials: Women with breast cancer ≤3 cm were recruited between February 2003 and May 2005. After breast-conserving surgery, a single dose of 5 Gy IORT boost was delivered using 50-kV x-rays to a depth of 10 mm from the applicator surface. This was followed by WBI to a total dose of 50 Gy in 25 fractions. Patients were reviewed at regular, predefined intervals. Late toxicities were recorded using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Late Radiation Morbidity Scoring systems. Results: Fifty-five patients completed both IORT boost and external-beam WBI. Median follow-up was 3.3 years (range, 1.4-4.1 years). There was no reported locoregional recurrence or death. One patient developed distant metastases. Grade 2 and 3 subcutaneous fibrosis was detected in 29 (53%) and 8 patients (15%), respectively. Conclusions: The use of IORT as a tumor bed boost using kV x-rays in breast-conserving therapy was associated with good local control but a clinically significant rate of grade 2 and 3 subcutaneous fibrosis.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

High-Dose-Rate Brachytherapy Boost Effect on Local Tumor Control in Young Women With Breast Cancer

Purpose: To evaluate the local control rate and complications of a single fraction of high-dose-rate brachytherapy (HDR BT) boost in women aged 45 yeas and younger after breast-conserving therapy. Methods and Materials: Between 1999 and 2007, 167 patients between the ages of 26 and 45 years old (72 were 40 years old or younger), with stages T1 to T2 invasive breast cancer with disease-free margin status of at least 5 mm after breast-conserving surgery received 46 to 50 Gy whole-breast irradiation plus a 7-Gy HDR-BT boost (“fast boost”). An axillary dissection was performed in 72.5% of the patients and sentinel lymph node biopsy in 27.5%. A supraclavicular area was irradiated in 19% of the patients. Chemotherapy was used in 86% of the patients and hormone treatment in 77%. Clinical nodes were present in 18% and pathological nodes in 29%. The pathological stage was pT0: 5%, pTis: 3%, pT1: 69% and pT2: 23%. Intraductal component was present in 40% and 28% were G3. Results: At a median follow-up of 92 months, 9 patients relapsed on the margin of the implant, and 1 patient in another quadrant, resulting in a 10-year local relapse rate of 4.3% and a breast relapse rate of 4.9%, with breast preservation in 93.4%; no case of mastectomy due to poor cosmesis arose. Actuarial 5- and 10-year disease-free, cause-specific, and overall survival rates were 87.9% and 85.8%, and 92.1% and 88.4%, and 92.1% and 87.3%, respectively. In a univariate analysis, triple-negative cases and negative hormone receptors did worse, but in a multivariate analysis, only the last factor was significant for local and breast control. Asymptomatic fibrosis G2 was recorded in 3 cases, and there were no other late complications. Cosmetic results were good to excellent in 97% of cases. Conclusions: A single dose of 7 Gy using the fast-boost technique is well tolerated, with a low rate of late complications and improved local tumor control in women aged 45 and younger, compared to published data. This approach is recommended in breast-preserving treatment.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial

Purpose: Conventionally fractionated whole-breast irradiation (WBI) with a boost takes approximately 6 to 7 weeks. We evaluated a short course of hypofractionated (HF), accelerated WBI in which therapy was completed in 3 weeks inclusive of a sequential boost. Methods and Materials: We delivered a whole-breast dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days, followed by a lumpectomy bed boost in 4 fractions of 3.33 Gy delivered once daily for a total of 15 treatment days. Acute toxicities were scored using Common Terminology Criteria for Adverse Events version 4. Late toxicities were scored using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scale. Cosmesis was scored using the Harvard Cosmesis Scale. Our primary endpoint was freedom from locoregional failure; we incorporated early stopping criteria based on predefined toxicity thresholds. Cosmesis was examined as a secondary endpoint. Results: We enrolled 83 women with stages 0 to IIIa breast cancer. After a median follow-up of 40 months, 2 cases of isolated ipsilateral breast tumor recurrence occurred (2 of 83; crude rate, 2.4%). Three-year estimated local recurrence-free survival was 95.9% (95% confidence interval [CI]: 87.8%-98.7%). The 3-year estimated distant recurrence-free survival was 97.3% (95% CI: 89.8%-99.3%). Three-year secondary malignancy-free survival was 94.3% (95% CI: 85.3%-97.8%). Twenty-nine patients (34%) had grade 2 acute toxicity, and 1 patient had a late grade 2 toxicity (fibrosis). One patient had acute grade 3 dermatitis, whereas 2 patients experienced grade 3 late skin toxicity. Ninety-four percent of evaluable patients had good or excellent cosmesis. Conclusions: Our phase 2 institutional study offers one of the shortest courses of HF therapy, delivered in 15 fractions inclusive of a sequential boost. We demonstrated expected low toxicity and high local control rates with good to excellent cosmetic outcomes. This fractionation scheme is feasible and well tolerated and offers women WBI in a highly convenient schedule.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study

Purpose: Stereotactic body radiation therapy (SBRT) boost to primary and nodal disease after chemoradiation has potential to improve outcomes for advanced non-small cell lung cancer (NSCLC). A dose escalation study was initiated to evaluate the maximum tolerated dose (MTD). Methods and Materials: Eligible patients received chemoradiation to a dose of 50.4 Gy in 28 fractions and had primary and nodal volumes appropriate for SBRT boost (<120 cc and <60 cc, respectively). SBRT was delivered in 2 fractions after chemoradiation. Dose was escalated from 16 to 28 Gy in 2 Gy/fraction increments, resulting in 4 dose cohorts. MTD was defined when ≥2 of 6 patients per cohort experienced any treatment-related grade 3 to 5 toxicity within 4 weeks of treatment or the maximum dose was reached. Late toxicity, disease control, and survival were also evaluated. Results: Twelve patients (3 per dose level) underwent treatment. All treatment plans met predetermined dose-volume constraints. The mean age was 64 years. Most patients had stage III disease (92%) and were medically inoperable (92%). The maximum dose level was reached with no grade 3 to 5 acute toxicities. At a median follow-up time of 16 months, 1-year local-regional control (LRC) was 78%. LRC was 50% at <24 Gy and 100% at ≥24 Gy (P=.02). Overall survival at 1 year was 67%. Late toxicity (grade 3-5) was seen in only 1 patient who experienced fatal bronchopulmonary hemorrhage (grade 5). There were no predetermined dose constraints for the proximal bronchial-vascular tree (PBV) in this study. This patient's 4-cc PBV dose was substantially higher than that received by other patients in all 4 cohorts and was associated with the toxicity observed: 20.3 Gy (P<.05) and 73.5 Gy (P=.07) for SBRT boost and total treatment, respectively. Conclusions: SBRT boost to both primary and nodal disease after chemoradiation is feasible and well tolerated. Local control rates are encouraging, especially at doses ≥24 Gy in 2 fractions. Toxicity at the PBV is a concern but potentially can be avoided with strict dose-volume constraints.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Effects of hyperbolic rotation in Minkowski space on the modeling of plasma accelerators in a Lorentz boosted frame

The effects of hyperbolic rotation in Minkowski space resulting from the use of Lorentz boosted frames of calculation on laser propagation in plasmas are analyzed. Selection of a boost frame at the laser group velocity is shown to alter the laser spectrum, allowing the use of higher boost velocities. The technique is applied to simulations of laser driven plasma wakefield accelerators, which promise much smaller machines and whose development requires detailed simulations that challenge or exceed current capabilities. Speedups approaching the theoretical optima are demonstrated, producing the first direct simulations of stages up to 1 TeV. This is made possible by a million times speedup thanks to a frame boost with a relativistic factor {gamma}{sub b} as high as 1300, taking advantage of the rotation to mitigate an instability that limited previous work.

71 CLASSICAL AND QUANTUM MECHANICS, GENERAL PHYSIC↗

(In)direct detection of boosted dark matter

We initiate the study of novel thermal dark matter (DM) scenarios where present-day annihilation of DM in the galactic center produces boosted stable particles in the dark sector. These stable particles are typically a subdominant DM component, but because they are produced with a large Lorentz boost in this process, they can be detected in large volume terrestrial experiments via neutral-current-like interactions with electrons or nuclei. This novel DM signal thus combines the production mechanism associated with indirect detection experiments (i.e. galactic DM annihilation) with the detection mechanism associated with direct detection experiments (i.e. DM scattering off terrestrial targets). Such processes are generically present in multi-component DM scenarios or those with non-minimal DM stabilization symmetries. As a proof of concept, we present a model of two-component thermal relic DM, where the dominant heavy DM species has no tree-level interactions with the standard model and thus largely evades direct and indirect DM bounds. Instead, its thermal relic abundance is set by annihilation into a subdominant lighter DM species, and the latter can be detected in the boosted channel via the same annihilation process occurring today. Especially for dark sector masses in the 10 MeV–10 GeV range, the most promising signals are electron scattering events pointing toward the galactic center. These can be detected in experiments designed for neutrino physics or proton decay, in particular Super-K and its upgrade Hyper-K, as well as the PINGU/MICA extensions of IceCube. This boosted DM phenomenon highlights the distinctive signatures possible from non-minimal dark sectors.

79 ASTRONOMY AND ASTROPHYSICS↗

Detecting boosted dark matter from the Sun with large volume neutrino detectors

We study novel scenarios where thermal dark matter (DM) can be efficiently captured in the Sun and annihilate into boosted dark matter. In models with semi-annihilating DM, where DM has a non-minimal stabilization symmetry, or in models with a multi-component DM sector, annihilations of DM can give rise to stable dark sector particles with moderate Lorentz boosts. We investigate both of these possibilities, presenting concrete models as proofs of concept. Both scenarios can yield viable thermal relic DM with masses O(1)-O(100) GeV. Taking advantage of the energetic proton recoils that arise when the boosted DM scatters off matter, we propose a detection strategy which uses large volume terrestrial detectors, such as those designed to detect neutrinos or proton decays. In particular, we propose a search for proton tracks pointing towards the Sun. We focus on signals at Cherenkov-radiation-based detectors such as Super-Kamiokande (SK) and its upgrade Hyper-Kamiokande (HK). We find that with spin-dependent scattering as the dominant DM-nucleus interaction at low energies, boosted DM can leave detectable signals at SK or HK, with sensitivity comparable to DM direct detection experiments while being consistent with current constraints. Our study provides a new search path for DM sectors with non-minimal structure.

79 ASTRONOMY AND ASTROPHYSICS↗

Effective viscosities in a hydrodynamically expanding boost-invariant QCD plasma

Background: The near-equilibrium properties of a QCD plasma can be encoded into transport coefficients such as bulk and shear viscosity. In QCD, the ratio of these transport coefficients to entropy density, ζ/$\textit{s}$ and η/$\textit{s}$, depends nontrivially on the plasma's temperature. This is unlike in conformal systems where they take constant values such as η/$\textit{s}$ = 1/(4π). Purpose: In this work, we show that in a (0 + 1)D boost-invariant fluid with no transverse expansion, a temperature-dependent ζ/$\textit{s(T)}$ or η/$\textit{s(T)}$ can be described by an equivalent effective viscosity $\langleζ/s\rangle_{\text{eff}}$ or $\langleη/s\rangle_{\text{eff}}$. This effective viscosity combines the actual temperature-dependent ζ/$\textit{s(T)}$ or η/$\textit{s(T)}$ with the temperature profile of the fluid. Further, we extend the concept of effective viscosity in systems with transverse expansion and discuss how effective viscosities can be used to identify families of ζ/$\textit{s(T)}$ and η /$\textit{s(T)}$ that lead to similar hydrodynamic evolution. Methods: The Navier-Stokes relativistic hydrodynamic equations are used to provide a first definition of effective viscosity, in (0 + 1)D and (1 + 1)D. In the (0 + 1)D case, the analysis is extended to Israel-Stewart-type second-order hydrodynamics to clarify the effect of higher-order hydrodynamics corrections on the effective viscosity. Results: In a boost-invariant fluid with no transverse expansion [(0 + 1)D], the effective viscosity is expressed as a simple integral of ζ/$\textit{s(T)}$ or η/$\textit{s(T)}$ over temperature, with a weight determined by the speed of sound of the fluid. The result is general for any equation of state with a moderate temperature dependence of the speed of sound, including the QCD equation of state. This definition of effective viscosity can be used to identify infinite families of ζ/$\textit{s(T)}$ or η/$\textit{s(T)}$ that produce essentially indistinguishable temperature profiles. In a boost-invariant cylindrical system [(1 + 1)D], a similar definition of effective viscosity is obtained in terms of characteristic trajectories in time and transverse direction. This leads to an infinite number of constraints on an infinite functional space for ζ/$\textit{s(T)}$ and η/$\textit{s(T)}$. Realistic examples are presented by using a finite number of constraints on a finite functional space. Conclusions: The definition of effective viscosity in a (0 + 1)D system clarifies how infinite families of ζ/$\textit{s(T)}$ and η/$\textit{s(T)}$ can result in nearly identical hydrodynamic temperature profiles. By extending the study to a boost-invariant cylindrical [(1 + 1)D] fluid, we identify an approximate but more general definition of effective viscosity that highlights the potential and limits of the concept of effective viscosity in fluids with limited symmetries.

70 PLASMA PHYSICS AND FUSION TECHNOLOGY↗

Search for inelastic boosted dark matter with the ICARUS detector at the Gran Sasso Underground National Laboratory

We present the result of a search for inelastic boosted dark matter using the data corresponding to an exposure of 0.13 kton · year , collected by the ICARUS T-600 detector during its 2012–2013 operational period at the INFN Gran Sasso Underground National Laboratory. The benchmark boosted dark matter model features a multiparticle dark sector with a U ( 1 ) ′ gauge boson, the dark photon. The kinetic mixing of the dark photon with the Standard Model photon allows for a portal between the dark sector and the visible sector. The inelastic boosted dark matter interaction occurs when a dark matter particle inelastically scatters with an electron in the ICARUS detector, producing an outgoing, heavier dark sector state which subsequently decays back down to the dark matter particle, emitting a dark photon. The dark photon subsequently couples to a Standard Model photon through kinetic mixing. The Standard Model photon then converts to an electron-positron pair in the detector. This interaction process provides a distinct experimental signature that consists of a recoil electron from the primary interaction and an associated electron-positron pair from the secondary vertex. After analyzing 4,134 triggered events, the search results in zero observed events. Exclusion limits are set in the dark photon mass and coupling ( m X , ε ) parameter space for several selected optimal boosted dark matter mass sets and cover previously unexplored parameter space. Published by the American Physical Society 2025

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗

The Voltage Boost Enabled by Luminescence Extraction in Solar Cells

A new physical principle has emerged to produce record voltages and efficiencies in photovoltaic cells, 'luminescence extraction.' This is exemplified by the mantra 'a good solar cell should also be a good LED.' Luminescence extraction is the escape of internal photons out of the front surface of a solar cell. Basic thermodynamics says that the voltage boost should be related to concentration ratio, C, of a resource by ..delta..V=(kT/q)ln{C}. In light trapping, (i.e. when the solar cell is textured and has a perfect back mirror) the concentration ratio of photons C={4n2}, so one would expect a voltage boost of ..delta..V=kT ln{4n2} over a solar cell with no texture and zero back reflectivity, where n is the refractive index. Nevertheless, there has been ambiguity over the voltage benefit to be expected from perfect luminescence extraction. Do we gain an open circuit voltage boost of ..delta..V=(kT/q)ln{n2}, ..delta..V=(kT/q)ln{2n2}, or ..delta..V=(kT/q)ln{4n2}? What is responsible for this voltage ambiguity ..delta..V=(kT/q)ln{4}=36mVolts? We show that different results come about, depending on whether the photovoltaic cell is optically thin or thick to its internal luminescence. In realistic intermediate cases of optical thickness the voltage boost falls in between; ln{n2}q..delta..V/kT)<;ln{4n2}.

14 SOLAR ENERGY↗

SU-F-BRD-06: Dosimetric Cost of a GTV Margin for Simultaneous Integrated Intra- Prostatic Boost Treatments

Purpose: Quantify the dosimetric cost for a margin around the MRI-defined high risk GTV for simultaneous integrated intra-prostatic boosts (SIIB) treated with RapidArc. Methods: For external beam radiotherapy of the prostate, a 3-7 mm PTV margin is typically used to account for setup and intra-fraction uncertainties after adjusting for inter-fraction motion. On the other hand, our current paradigm is to treat the MRI-defined high risk GTV with no margin. In this work, 11 patients treated SIIB (7 post-prostatectomy, 4 intact prostate) with RapidArc were re-planned with 1-5 mm margins around the GTV to quantify dosimetric effects. Two 358 degree, 10 MV RapidArcs were used to deliver 68 Gy (76.5 Gy boost) to the post-prostatectomy patients and 80 Gy (86 Gy boost) to the intact prostates. Paired, two tail t-tests were used to determine if there were any significant differences (p<0.05) in the total MUs and dosimetric parameters used to evaluate rectum, bladder, and PTV dose with and without margin. Results: The average GTV volume without margin was 8.1cc (2.8% of the PTV volume) while the average GTV volume with a 5 mm margin was 20.1cc (9.0% of the PTV volume). GTV volumes ranged from 0.2% of the PTV volume up to 33.0%. Despite these changes in volume, the only statistical difference was found for the rectal V65 Gy with a 5 mm margin (18.6% vs. 19.4%; p-value = 0.026) when all patients were considered as a single group. No difference was found when analyzed as two groups. The rectum V40Gy, bladder V40Gy and V65Gy, PTV Dmax and D95% or the total MUs did not show any significant difference for any margin. Conclusion: A 4 mm margin on the high risk GTV is possible with no statistically significant change in dosimetry or total MUs. Further work will assess the appropriate margin required for intra-prostatic boosts.

60 APPLIED LIFE SCIENCES↗

SU-F-T-40: Can CBCT Images Be Used for Volume Studies of Prostate Seed Implants for Boost Treatment?

Purpose: In our clinic, the planning CT is used for definitive and boost low-dose-rate (LDR) brachytherapy treatments to determine the ultrasound volume in the operating room (OR) at the time of the implant. While the CT overestimation of OR volume is known, a larger estimation discrepancy has been observed for boost treatments. A possible reason is the prostate size reduction during EBRT for boost patients. Since cone-beam CT (CBCT) is often used as routine imaging guidance of EBRT, this prostate volume change may be captured. This study investigates if CBCT taken during EBRT includes the volume change information and therefore beats CT in estimating the prostate OR volumes. Methods: 9 prostate patients treated with EBRT (45Gy in 1.8Gy per fractions to the whole pelvis) and I-125 seed implants (108Gy) were involved in this study. During EBRT, CBCT image guidance was performed on a weekly basis. For each patient, the prostate volumes on the first and the last available CBCT images were manually contoured by a physician. These volumes were then compared to each other and with the contoured volumes from the planning CT and from the ultrasound images in the OR. Results: The first and the last CBCT images did not show significant prostate volume change. Their average +/− standard deviation of prostate volumes were 24.4cc+/−14.6cc and 29.9cc+/−16.1cc, respectively (T-test p=0.68). The ratio of the OR volume to the last CBCT (0.71+/−0.21) was not significantly different from the ratio of OR volumes to the planning CT (0.61+/−0.13) (p=0.25). Conclusion: In this study, CBCT does not show significant prostate volume changes during EBRT. CBCT and CT volumes are quite consistent and no improvement of volume estimation using CBCT is observed. The advantage of CBCT as a replacement of CT for volume study of boost LDR brachytherapy is limited.

60 APPLIED LIFE SCIENCES↗

SU-F-T-203: High Dose Definitive Proton Therapy with Integrated Boost to Hypoxic Subvolumes Determined by [18F]-Fluoromisonidazole (FMISO) PET/CT for Patients with Recurrent Chordomas Using Intensity Modulated Proton Therapy (IMPT)

Purpose: Recurrent chordomas are difficult to control locally. This dosimetric study investigates the feasibility of dose escalation to hypoxic regions, visualized on FMISO-PET, while respecting the dose constraints to the neighboring normal tissues/organs. We propose to deliver a higher dose to the areas of hypoxia (84.5Gy) using IMPT with the goal of improving local control. Methods: We currently have four patients with hypoxic subvolumes (HSV) greater than 10cc from the FMISO-PET image. The HSV was delineated based on the standardized uptake values of greater than 1.4 times of the muscle mean. Gross tumor volume (GTV) was delineated using planning CT with the assistance of MRI fusion. The dose scheme is 50.4Gy RBE to CTV in 1.8Gy fractions, followed by an integrated boost of 27.0Gy RBE to GTV in 1.8Gy fractions and 34.5Gy RBE to HSV in 2.3Gy fractions. IMPT integrated boost plans were optimized with multi-criteria optimization (MCO). Posterior-anterior beam angles were used for these plans. We also propose using two posterior oblique fields to boost HSV to spare the skin folding. A medium spot size with 8mm to 15 mm (σ) in air at isocenter with energies from 220 MeV down to 90 MeV was used. Aperture was used for the medium spot size. A small spot size of 2.5 mm to 4.5 mm (σ) in air at isocenter with energies from 240 MeV down to 70 MeV was also proposed. Target coverage and dose to OARs were evaluated. Results: For the sacral chordoma patient that has been planned, the target homogeneity index is 3.2% for HSV, 55.9% for CTV and 11.9% for GTV. The max dose is 77GyRBE to rectum, 86.2GyRBE to sacral nerves and 73.9GyRBE to cauda equina. Conclusion: IMPT with integrated high dose boost to HSV determined from FMISO PET image is feasible. OAR dose constraints were met.

60 APPLIED LIFE SCIENCES↗